Date Collected: **08/12/2025** Date Received: **08/12/2025** Date Reported: **09/02/2025** Fasting: **No**

Ordered Items: **Lupus Anticoagulant Comp; CBC With Differential/Platelet; Killer Immunoglobulin-like Rec; Antinuclear Ab 9 by Multiplex; HLA-DRB1 (HR) DRB345 (IR); Antiphosphatidylserine IgG/M/A; Anticardiolip Ab, IgA/G/M, Qn; Beta-2 Glycoprotein I Ab,G,A,M; HLA DQA1 (IR); HLA DQB1 (HR); HLA-A (IR); HLA-B (IR); HLA-C (HR); HLA Class I Antibody HD; HLA Class II Antibody HD; Anti-Mullerian Hormone (AMH); Factor V Leiden Mutation; Complement C4, Serum; Folate (Folic Acid), Serum; TSH; Complement C3, Serum; Rheumatoid Factor (RF); Thyrotropin Receptor Ab, Serum; Vitamin D, 25-Hydroxy; Anti-CCP Ab, IgG/IgA; Homocyst(e)ine; Immunoglobulin E, Total; Thyroxine (T4); Triiodothyronine (T3); Thyroglobulin Antibody; Request Problem; Immunoglobulin G, Qn, Serum; Immunoglobulin A, Qn, Serum; Immunoglobulin M, Qn, Serum; Thyroid Peroxidase (TPO) Ab; Blood Drawing**

Date Collected: **08/12/2025**

Lupus Anticoagulant Comp

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Dilute Prothrombin Time(dPT) [01]	41.4	35.0	07/03/2025	sec	0.0-47.6
dPT Confirm Ratio [01]	0.96	1.12	07/03/2025	Ratio	0.00-1.34
Thrombin Time [01]	21.0	21.5	07/03/2025	sec	0.0-23.0
. [02]					
Lupus Anticoagulant Reflex [01]					
PTT-LA [01]	42.0	36.3	07/03/2025	sec	0.0-43.5
dRVVT [01]	34.1	28.7	07/03/2025	sec	0.0-47.0
Lupus Reflex Interpretation [01]	Comment: No lupus anticoagulant was detected.	Comment:	07/03/2025		

CBC With Differential/Platelet

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
WBC [02]	8.3	5.6	11/30/2023	x10E3/uL	3.4-10.8
RBC [02]	4.02	4.64	11/30/2023	x10E6/uL	3.77-5.28
Hemoglobin [02]	11.9	13.7	11/30/2023	g/dL	11.1-15.9
Hematocrit [02]	36.6	41.2	11/30/2023	%	34.0-46.6
MCV [02]	91	89	11/30/2023	fL	79-97
MCH [02]	29.6	29.5	11/30/2023	pg	26.6-33.0
MCHC [02]	32.5	33.3	11/30/2023	g/dL	31.5-35.7
RDW [02]	12.6	12.1	11/30/2023	%	11.7-15.4
Platelets [02]	246	333	11/30/2023	x10E3/uL	150-450
Neutrophils [02]	61			%	Not Estab.
Lymphs [02]	28			%	Not Estab.
Monocytes [02]	7			%	Not Estab.
Eos [02]	2			%	Not Estab.
Basos [02]	1			%	Not Estab.
Neutrophils (Absolute) [02]	5.2			x10E3/uL	1.4-7.0
Lymphs (Absolute) [02]	2.3			x10E3/uL	0.7-3.1
Monocytes(Absolute) [02]	0.6			x10E3/uL	0.1-0.9
Eos (Absolute) [02]	0.1			x10E3/uL	0.0-0.4
Baso (Absolute) [02]	0.0			x10E3/uL	0.0-0.2

CBC With Differential/Platelet (Cont.)

Immature Granulocytes [02]	1		%	Not Estab.
Immature Grans (Abs) [02]	0.1		x10E3/uL	0.0-0.1

Killer Immunoglobulin-like Rec

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
2DL1 [03]	Present KIR2DL1*0010101-0010107,00102,00103,0020101-0020144,0020201, KIR2DL1*0020202,0020301,0020302,00204,0020501-0020503, KIR2DL1*00301,0030201-0030298,00303-00309,0031001-0031004, KIR2DL1*00311,0031201,0031202,00313,0031401,0031402,00315, KIR2DL1*0031601,0031602,00317,0031801-0031803,0031901, KIR2DL1*0031902,0032001-0032004,0040102,0080101,0080102, KIR2DL1*009,010,01201,01202,014-021,02201,02202,023,025-028, KIR2DL1*030,031,0320101N,0320102N,0320103N,033,034,036, KIR2DL1*0370101,0370102,0370201,0370202,038,0400101,0400102, KIR2DL1*0430101-0430105,044,0450101N,0450102N,0450103N, KIR2DL1*046,0470101,0470102,048,049,053,0570101,0570102, KIR2DL1*0590101,0590102,060-063,0640101,0640102,065-068, KIR2DL1*0690101,0690102,071-077,0780101-0780103,079,082, KIR2DL1*0830101,0830102,0850101-0850103,086,0870101-0870103, KIR2DL1*088,0890101,0890102,090,0910101,0910102,0930101, KIR2DL1*0930102,094N,0950101-0950103,0970101,0970102,098, KIR2DL1*0990101-0990103,1010101,1010102,102,1030101,1030102, KIR2DL1*1050101-1050103,1070101,1070102,108,1090101-1090103, KIR2DL1*110,1110101-1110103,112,1130101,1130102, 1150101-1150103, KIR2DL1*1170101,1170102,118,1190101,1190102,120,1210101, KIR2DL1*1210102,122,123,1250101,1250102,1260101,1260102, KIR2DL1*127,128,1290101,1290102,130,131	Present 07/03/2025		
2DL2 [03]	Absent	Absent 07/03/2025		
2DL3 [03]	Present KIR2DL3*0010101-0010115,00102-00112,0020101-0020103,003, KIR2DL3*004,00501-00503,006,007,008N,009-011,01201,01202, KIR2DL3*013-017,01801,01802,019-031,034-037	Present 07/03/2025		
2DL4 [03]	Present KIR2DL4*0010301-0010310,00202,003,004,0050101-0050107,00503, KIR2DL4*00504,007,0080101-0080108,00803,0080401,0080402, KIR2DL4*0110101-0110104,01102,01201,01202,013,014,018-031, KIR2DL4*034,037,041,044,045,047-049,051,053,055-059	Present 07/03/2025		
2DL5 [03]	Present KIR2DL5*0010101-0010106,00104-00108,0010901,0010902,003, KIR2DL5*004,00601-00603,0070101,0070102,0080101,0080102, KIR2DL5*00802-00805,011,01201,01202,01301,01303,01304, KIR2DL5*014,015,018-020,0230101,0230102,024,025,027-031, KIR2DL5*0330101,0330102,0340101,0340102,038,040,042	Present 07/03/2025		
2DS1 [03]	Present KIR2DS1*0020101-0020118,00202,00301,00302,004,00501,00502, KIR2DS1*006,008-011,0120101,0120102,013	Present 07/03/2025		
2DS2 [03]	Absent	Absent 07/03/2025		
2DS3 [03]	Absent	Absent 07/03/2025		
2DS4 FUL [03]	Absent	Absent 07/03/2025		

Killer Immunoglobulin-like Rec (Cont.)

2DS4 DEL [03]	Present	Present	07/03/2025

KIR2DS4*0030101-0030104,0060101,0060102,007-010,012,018

2DS5 [03]	Present	Present	07/03/2025

KIR2DS5*001,0020101-0020133,00202-00204,0020501-0020503,
KIR2DS5*00206,0020701,0020702,003,004,00501,00502,0060101,
KIR2DS5*0060102,0070101,0070102,00801,00802,009-011,01201,
KIR2DS5*01202,013-015,017-020,0210101,0210102,022,0230101,
KIR2DS5*0230102,024,0250101,0250102,026,0270101,0270102,
KIR2DS5*029-038

3DL1 [03]	Present	Present	07/03/2025

KIR3DL1*0010101-0010122,00102-00107,0010801-0010803,00109,
KIR3DL1*0040501,0040502,0070101-0070106,00702,00703,0070401,
KIR3DL1*0070402,0080101-0080104,0090101-0090104,
0150101-0150103,
KIR3DL1*0150201-0150221,0150222Q,0150223,01503-01509,016,
KIR3DL1*0170101,0170102,01702,018,0200101-0200103,023,
KIR3DL1*024N,0250101-0250103,026,02701,02702,028,030,
0310101,
KIR3DL1*0310102,03102,032,033,037,043,051,052,062,066-068,
KIR3DL1*070,074,076,077,079,080,081N,086,088-090,092,093,
KIR3DL1*094N,095,096,101-103,112,114,116,118,121,137,141,
KIR3DL1*1420101,1420102,143,1440101,1440102,145,1470101,
KIR3DL1*1470102,151,152,155,157,169,1700101,1700102,171,
KIR3DL1*174,1750101,1750102,179-182

3DL2 [03]	Present	Present	07/03/2025

KIR3DL2*0010101-0010111,00102,0010301-0010305,00104-00107,
KIR3DL2*00109-00111,0020101-0020115,00202-00207,0030101,
KIR3DL2*0030102,00302-00304,004,0050101,0050102,00502,
KIR3DL2*00503,00601,00602,0070101-0070114,00702-00711,
KIR3DL2*0071201,0071202,0071301,0071302,0080101-0080103,
KIR3DL2*00802,01001-01005,01101-01103,012,01301-01303,
KIR3DL2*015-017,0180101,0180102,020-035,038-041,04301,
KIR3DL2*04302,044-049,051-059,06001,06002,061,063-073,
KIR3DL2*075-077,07901,07902,080-083,085-098,10001,10002,
KIR3DL2*101-105,10601,10701,10801,109,11001,11002,111,
KIR3DL2*113-117,1180101-1180103,119,1200101,1200102,121,
KIR3DL2*1220101,1220102,123,124,1250101,1250102,126,127,
KIR3DL2*129N,130,131N,132,134,1350101,1350102,136-138,
KIR3DL2*1390101,1390102,140,141N,142,143Q,144,145

3DL3 [03]	Present	Present	07/03/2025

KIR3DL3*0010101-0010104,0010201-0010203,00103-00105,0020101,
KIR3DL3*0020102,0020201-0020204,00203-00205,0020601-0020605,
KIR3DL3*0020701-0020703,00208-00211,0030101-0030109,0030112,
KIR3DL3*00302-00304,00401,0040201-0040204,00403,005,
0060101-0060103,
KIR3DL3*00602,00603,0070101-0070105,00801,00802,
0090101-0090107,
KIR3DL3*00902-00906,01001-01004,01101-01105,012,01301,
KIR3DL3*0130201,0130202,01303-01309,01401,0140201-0140206,
KIR3DL3*01403-01414,01501-01503,01601,01602,01701,01702,
KIR3DL3*01801,01802,019,020,02101,02102,022,023,0250101,
KIR3DL3*02502,02601,02602,02701-02705,02801,02802,029-040,
KIR3DL3*0410101-0410103,042-047,04801,04802,04901,04902,
KIR3DL3*050-077,079,080N,081,083-088,090-106,10701,10801,

Killer Immunoglobulin-like Rec (Cont.)

KIR3DL3*10802,1090101,1100101,111-118

3DS1 [03]	Present	Present	07/03/2025

KIR3DS1*010,0130101-0130113,0130115-0130132,01302-01307,
KIR3DS1*01309-01315,014,045-048,04901N,04902N,055,058,
KIR3DS1*082-085,104-108,122,1230101-1230103,1240101,1240102,
KIR3DS1*1250101,1250102,1270101,1270102,1280101,1280102,
KIR3DS1*129,1300101,1300102,131,132,1330101,1330102,134-136

2DP1 [03]	Present	Present	07/03/2025

KIR2DP1*00101,0010201-0010212,00103,0010401,0010402,
00105-00108,
KIR2DP1*0020101-0020127,00202,0020301-0020304,00204,00205,
KIR2DP1*0030101-0030108,00302,00303,0040101,0040102,007,
KIR2DP1*0080101,0080102,010,013,015,0160101-0160104,0160201,
KIR2DP1*0160202,01603,017-020,02101,02102,022,0250101,
KIR2DP1*0250102,0250201-0250204,026,027,0280101-0280103,
KIR2DP1*029-031,0320101,0320102,033,0340101,0340102,035-037

3DP1 [A, 03]	Present	Present	07/03/2025

KIR3DP1*0030101-0030105,0030201-0030221,00303,0030401,
0030402,
KIR3DP1*00305,0030601,0030602,00307-00320,00501,00502,
KIR3DP1*0060101-0060105,00602,0060301,0060302,00604-00606,
KIR3DP1*008,0090107,0100101,0100102,01002-01007,013,
0140101-0140103,
KIR3DP1*01402,0150101-0150103,01502,01503,01601,01602,
KIR3DP1*017-026,0270101,0270102,0280101,0280102,029-031,
KIR3DP1*0320101-0320103,033-045,048-055,0560101,0560102,
KIR3DP1*05602,058,0590101,0590102,0610101,0610102,062,
KIR3DP1*064,0650101,0650102,06502,066-069,07001,07002,
KIR3DP1*071-073,076-079,081-083,087,088,0890101,0890102,
KIR3DP1*090-094
KIR interpretation based on IPD-KIR database
version 2.14.0

Comment: [03]

This test was performed using Polymerase Chain Reaction (PCR) and
Sequence Specific Oligonucleotide Probes (SSOP) (Luminex) technique.
Sequence Based Typing (SBT) may be used as a supplemental method
when necessary.
If you have questions, please call HLA customer service at
1-800-533-1037 or email at HLACS@Labcorp.com.

Antinuclear Ab 9 by Multiplex

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Anti-DNA (DS) Ab Qn [02]	2		IU/mL	0-9
			Negative <5	
			Equivocal 5 - 9	
			Positive >9	
RNP Antibodies [02]	0.2		AI	0.0-0.9
Smith Antibodies [02]	<0.2		AI	0.0-0.9
Antiscleroderma-70 Antibodies [02]	0.2		AI	0.0-0.9
Sjogren's Anti-SS-A [02]	<0.2		AI	0.0-0.9

Date Collected: **08/12/2025**

Antinuclear Ab 9 by Multiplex (Cont.)

Sjogren's Anti-SS-B [02]	<0.2		AI	0.0-0.9
Antichromatin Antibodies [02]	0.4		AI	0.0-0.9
Anti-Jo-1 [02]	<0.2		AI	0.0-0.9
Anti-Centromere B Antibodies [02]	<0.2		AI	0.0-0.9

See below: [02]

Autoantibody	Disease Association	
	Condition	Frequency
Antinuclear Antibody, Direct (ANA-D)	SLE, mixed connective tissue diseases	
dsDNA	SLE	40 - 60%
Chromatin	Drug induced SLE	90%
	SLE	48 - 97%
SSA (Ro)	SLE	25 - 35%
	Sjogren's Syndrome	40 - 70%
	Neonatal Lupus	100%
SSB (La)	SLE	10%
	Sjogren's Syndrome	30%
Sm (anti-Smith)	SLE	15 - 30%
RNP (U1 nRNP, anti-ribonucleoprotein)	Mixed Connective Tissue Disease	95%
	SLE	30 - 50%
	Polymyositis and/or Dermatomyositis	20%
Scl-70 (antiDNA topoisomerase)	Scleroderma (diffuse)	20 - 35%
	Crest	13%
Jo-1	Polymyositis and/or Dermatomyositis	20 - 40%
Centromere B	Scleroderma - Crest variant	80%

HLA-DRB1 (HR) DRB345 (IR)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
DRB1 [03]		DRB1*03:01:01:01		
DRB1 [03]		DRB1*15:01:01:01 The following alleles could not be ruled out: DRB1* 15:01:01:01/15:01:01:02/15:01:01:03/15:01:01:04 /15:01:01:05/15:01:01:06/15:01:01:07/15:01:01:08 /15:01:01:09/15:01:01:10/15:01:01:11/15:01:01:12 /15:01:01:14/15:01:01:15/15:01:01:16/15:01:01:17 /15:01:01:18/15:01:01:21/15:01:01:22/15:01:01:23		

Date Collected: **08/12/2025**

HLA-DRB1 (HR) DRB345 (IR) (Cont.)

/15:01:01:24/15:01:01:25/15:01:01:26/15:01:01:28
/15:01:01:29/15:01:01:30/15:01:01:31
DRB1* 03:01:01:01/03:01:01:02/03:01:01:05/03:01:01:06
/03:01:01:07/03:01:01:08/03:01:01:09/03:01:01:10
/03:01:01:12/03:01:01:14/03:01:01:16/03:01:01:17
/03:01:01:18/03:01:01:19/03:01:01:20/03:01:01:22
/03:01:01:26/03:01:01:27/03:01:31

DRB3 [03]

DRB3*02:02:01:01

DRB3 [03]

DRB3*-
The following alleles could not be ruled out:
DRB3* 02:02:01:01/02:02:01:03/02:02:01:10/02:02:01:12
/02:02:01:15/02:02:23/02:02:30/02:02:31/02:02:34
/02:02:35/02:144/02:167/02:168/02:188/02:189/02:204
/02:205/02:211/02:212

DRB4 [03]

DRB4*-

DRB4 [03]

DRB4*-

DRB5 [03]

DRB5*01:01:01:01

DRB5 [03]

DRB5*-
The following alleles could not be ruled out:
DRB5* 01:01:01:01/01:01:01:03
HLA allele interpretation for all loci based on IMGT/HLA database version 3.58.0
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
The FDA has determined that such clearance or approval is not necessary.
HLA Lab CLIA ID Number 34D0954530
HISTOCOMPATIBILITY SECTION DIRECTOR: Ruth P. Koester, PhD, F(ACHI)

HLA Methodology [03]

HLA results were obtained using "Next Generation Sequencing" (NGS). Supplemental procedures based on sequence based typing (SBT) and/or sequence specific oligonucleotide probes (SSOP) may be used as needed to obtain the required resolution.
If you have questions, please call HLA customer service at 1-800-533-1037 or email at HLACS@Labcorp.com.

Antiphosphatidylserine IgG/M/A

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Antiphosphatidylserine IgM [01]	13	10 07/03/2025	Units	0-30
	Effective August 25, 2025 117910 Antiphosphatidylserine IgM reference interval will be changing to : 0 - 50 Units			
Antiphosphatidylserine IgA [01]	<1	2 07/03/2025	APS Units	0-19

Antiphosphatidylserine IgG/M/A (Cont.)

Effective August 25, 2025 117926 Antiphosphatidylserine IgA
reference interval will be changing to : 0 - 3 Units

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Antiphosphatidylserine IgG [01]	<9	<9	07/03/2025	Units	0-30

Effective August 25, 2025 117927 Antiphosphatidylserine IgG
reference interval will be changing to : 0 - 20 Units

Anticardiolip Ab, IgA/G/M, Qn

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Anticardiolipin Ab,IgG,Qn [02]	<9		GPL U/mL	0-14
		Negative:	<15	
		Indeterminate:	15 - 20	
		Low-Med Positive:	>20 - 80	
		High Positive:	>80	
Anticardiolipin Ab,IgM,Qn [02]	12		MPL U/mL	0-12
		Negative:	<13	
		Indeterminate:	13 - 20	
		Low-Med Positive:	>20 - 80	
		High Positive:	>80	
Anticardiolipin Ab,IgA,Qn [02]	<9		APL U/mL	0-11
		Negative:	<12	
		Indeterminate:	12 - 20	
		Low-Med Positive:	>20 - 80	
		High Positive:	>80	

Beta-2 Glycoprotein I Ab,G,A,M

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Beta-2 Glycoprotein I Ab, IgG [01]	<9	<9	07/03/2025	GPI IgG units	0-20
Please Note: [01]	The reference interval reflects a 3SD or 99th percentile interval, which is thought to represent a potentially clinically significant result in accordance with the International Consensus Statement on the classification criteria for definitive antiphospholipid syndrome (APS). J Thromb Haem 2006;4:295-306.				
Beta-2 Glycoprotein I Ab, IgA [01]	<9	<9	07/03/2025	GPI IgA units	0-25
Please Note: [01]	The reference interval reflects a 3SD or 99th percentile interval, which is thought to represent a potentially clinically significant result in accordance with the International Consensus Statement on the classification criteria for definitive antiphospholipid syndrome (APS). J Thromb Haem 2006;4:295-306.				
Beta-2 Glycoprotein I Ab, IgM [01]	<9	<9	07/03/2025	GPI IgM units	0-32
Please Note: [01]	The reference interval reflects a 3SD or 99th percentile interval, which is thought to represent a potentially clinically significant result in accordance with the International Consensus Statement on the classification criteria for definitive antiphospholipid syndrome (APS). J Thromb Haem 2006;4:295-306.				

Date Collected: **08/12/2025**

HLA DQA1 (IR)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
DQA1 [03]	DQA1*01:FHPPP			
DQA1 [03]	DQA1*05:EZUCM			

HLA DQB1 (HR)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
HLA DQB Sequencing [03]	DQB1*02:01:01:01			
HLA DQB Sequencing [03]	DQB1*06:02:01:01 The following alleles could not be ruled out: DQB1* 06:02:01:01/06:02:01:05/06:02:01:08/06:02:01:13 /06:02:01:15/06:02:01:16/06:02:01:17/06:02:01:20 /06:02:01:21/06:02:01:28/06:02:01:29/06:02:01:32 /06:02:01:35/06:02:01:36/06:02:01:38/06:02:01:39 /06:416:01:01Q/06:02:49/06:446 DQB1* 02:01:01:01/02:01:01:03/02:01:01:04/02:01:01:05 /02:01:01:07/02:01:01:12/02:01:01:13/02:01:01:14 /02:01:01:15/02:01:01:18/02:01:01:22/02:01:01:25 /02:01:46/02:163N/02:198/02:202			

HLA-A (IR)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
HLA-A [03]	A*02:06:01G			
HLA-A [03]	A*30:02:01G			

HLA-B (IR)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
HLA-B [03]	B*07:02:01G			
HLA-B [03]	B*18:01:01G			

HLA-C (HR)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
HLA-C [03]	C*05:01:01:01			
HLA-C [03]	C*07:02:01:03 The following alleles could not be ruled out: C* 07:02:01:03/07:02:01:09/07:02:01:10/07:02:01:11 /07:02:01:23/07:02:01:28/07:02:01:35/07:02:01:105 /07:02:01:112/07:02:01:115/07:02:01:183/07:02:01:186			

HLA-C (HR) (Cont.)

```
          /07:02:01:189/07:02:01:190/07:02:01:197/07:02:01:204
C*        05:01:01:01/05:01:01:16/05:01:01:82/05:01:01:84
```

HLA Class I Antibody HD

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
HLA Ab HD 1 [03]				

```
Please refer to the following specimen for additional lab results.
See 224-142-6906-1 for results
```

Comment: [03]

```
This test was performed using solid phase (Luminex) testing.
If you have questions, please call HLA customer service at
1-800-533-1037 or email at HLACS@Labcorp.com.
```

HLA Class II Antibody HD

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
HLA Ab HD 2 [03]	0		% CPRA	

```
                                    Low Positive          < 30
                                    Medium Positive  30 -  70
                                    High Positive         > 70
Negative
```

Anti-Mullerian Hormone (AMH)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Anti-Mullerian Hormone (AMH) [04]	0.828	1.14 07/03/2025	ng/mL	

```
For assays employing antibodies, the possibility exists for
interference by heterophile antibodies in the samples.1

1.Kricka L.  Interferences in Immunoassays - still a threat.
 Clin. Chem. 2000; 46: 1037-1038.

This test was developed and its performance characteristics
determined by LabCorp. It has not been cleared or approved
by the Food and Drug Administration.
Reference Range:
Females 31 - 35y: 0.66 - 8.75
Median  3.00
AMH concentrations of >= 1.06 ng/mL is correlated with a
better response to ovarian stimulation, produced more
retrievable oocytes and higher odds of live birth according
to Gleicher et al.  Fertility and Sterility. 2010:
94:2824-2827.  The current AMH test method correlates with
the study method with a slope of 0.94.
Females at risk of ovarian hyperstimulation syndrome or
polycystic ovarian syndrome (PCOS) may exhibit elevated
serum AMH concentrations.   AMH levels from PCOS patients
may be 2 to 5 fold higher than age-appropriate reference
interval values.
Granulosa cell tumors of the ovary may secrete AMH along
with other tumor markers.  Elevated AMH is not specific for
malignancy, and the assay should not be used exclusively to
```

Date Collected: **08/12/2025**

Anti-Mullerian Hormone (AMH) (Cont.)

diagnose or exclude an AMH-secreting ovarian tumor.

Factor V Leiden Mutation

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Factor V Leiden [05]	Result: c.1601G>A (p.Arg534Gln) - Not Detected This result is not associated with an increased risk for venous thromboembolism. See Additional Clinical Information and Comments.			
Comment [05]	Additional Clinical Information: Venous thromboembolism is a multifactorial disease influenced by genetic, environmental, and circumstantial risk factors. The c.1601G>A (p. Arg534Gln) variant in the F5 gene, commonly referred to as Factor V Leiden, is a genetic risk factor for venous thromboembolism. Heterozygous carriers of this variant have a 6- to 8-fold increased risk for venous thromboembolism. Individuals homozygous for this variant (ie, with a copy of the variant on each chromosome) have an approximately 80-fold increased risk for venous thromboembolism. Individuals who carry both a c.*97G>A variant in the F2 gene and Factor V Leiden have an approximately 20-fold increased risk for venous thromboembolism. Risks are likely to be even higher in more complex genotype combinations involving the F2 c.*97G>A variant and Factor V Leiden (PMID: 33674767). Additional risk factors include but are not limited to: deficiency of protein C, protein S, or antithrombin III, age, male sex, personal or family history of deep vein thromboembolism, smoking, surgery, prolonged immobilization, malignant neoplasm, tamoxifen treatment, raloxifene treatment, oral contraceptive use, hormone replacement therapy, and pregnancy. Management of thrombotic risk and thrombotic events should follow established guidelines and fit the clinical circumstance. This result cannot predict the occurrence or recurrence of a thrombotic event. Comment: Genetic counseling is recommended to discuss the potential clinical implications of positive results, as well as recommendations for testing family members. Genetic Coordinators are available for health care providers to discuss results at 1-800-345-GENE (4363). Test Details: Variant Analyzed: c.1601G>A (p. Arg534Gln), referred to as Factor V Leiden Methods/Limitations: DNA analysis of the F5 gene (NM_000130.5) was performed by PCR amplification followed by electrophoresis. The diagnostic sensitivity is >99%. Results must be combined with clinical information for the most accurate interpretation. Molecular-based testing is highly accurate, but as in any laboratory test, diagnostic errors may occur. False positive or false negative results may occur for reasons that include genetic variants, blood transfusions, bone marrow transplantation, somatic or tissue-specific mosaicism, mislabeled samples, or erroneous representation of family relationships. This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the			

Date Collected: **08/12/2025**

Factor V Leiden Mutation (Cont.)

Food and Drug Administration.
References:

Bhatt S, Taylor AK, Lozano R, Grody WW, Griffin JH; ACMG Professional Practice and Guidelines Committee. Addendum: American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med. 2021 Mar 5. doi: 10.1038/s41436-021-01108-x. PMID: 33674767.

Kujovich JL. Factor V Leiden Thrombophilia. 1999 May 14 (Updated 2018 Jan 4). In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews(R) (Internet). Seattle (WA): University of Washington, Seattle; 1993-2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1368/

Zhang S, Taylor AK, Huang X, Luo B, Spector EB, Fang P, Richards CS; ACMG Laboratory Quality Assurance Committee. Venous thromboembolism laboratory testing (factor V Leiden and factor II c.*97G>A), 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018 Dec;20(12):1489-1498. doi: 10.1038/s41436-018-0322-z. Epub 2018 Oct 5. PMID: 30297698.

Reviewed By: [05]

Technical Component performed at Labcorp RTP
Professional Component performed by:
Binu Porath, PhD, FACMG
BPTGD4, Labcorp, 1912 TW Alexander Drive
RTP NC 27709

Complement C4, Serum

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Complement C4, Serum [02]	15		mg/dL	12-38

Folate (Folic Acid), Serum

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Folate (Folic Acid), Serum [02]	>20.0	>20.0 07/03/2025	ng/mL	>3.0

Note: [02]

A serum folate concentration of less than 3.1 ng/mL is considered to represent clinical deficiency.

TSH

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
TSH [02]	1.640		uIU/mL	0.450-4.500

Complement C3, Serum

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Complement C3, Serum [02]	106		mg/dL	82-167

Rheumatoid Factor (RF)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Rheumatoid Factor (RF) [02]	<10.0		IU/mL	<14.0

Date Collected: **08/12/2025**

Thyrotropin Receptor Ab, Serum

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Thyrotropin Receptor Ab, Serum [01]	<1.10	<1.10 07/03/2025	IU/L	0.00-1.75

Vitamin D, 25-Hydroxy

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Vitamin D, 25-Hydroxy [02]	47.0		ng/mL	30.0-100.0

Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2).

1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press.
2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.

Anti-CCP Ab, IgG/IgA

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Anti-CCP Ab, IgG/IgA [02]	7		units	0-19

Negative	<20
Weak positive	20 - 39
Moderate positive	40 - 59
Strong positive	>59

Homocyst(e)ine

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Homocyst(e)ine [02]	5.6	6.4 07/03/2025	umol/L	0.0-14.5

Immunoglobulin E, Total

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Immunoglobulin E, Total [01]	9	9 07/03/2025	IU/mL	6-495

Thyroxine (T4)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Thyroxine (T4) [02]	6.9		ug/dL	4.5-12.0

Triiodothyronine (T3)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Triiodothyronine (T3) [02]	97	100 07/03/2025	ng/dL	71-180

Thyroglobulin Antibody

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Thyroglobulin Antibody [02]	<1.0		IU/mL	0.0-0.9

Date Collected: **08/12/2025**

Thyroglobulin Antibody (Cont.)

Thyroglobulin Antibody measured by Beckman Coulter Methodology
It should be noted that the presence of thyroglobulin antibodies may not be pathogenic nor diagnostic, especially at very low levels. The assay manufacturer has found that four percent of individuals without evidence of thyroid disease or autoimmunity will have positive TgAb levels up to 4 IU/mL.

Request Problem

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Request Problem [05]				

Our records indicate this order may be a duplicate request for cytogenetic testing. Please contact CMBP Customer Service at 800-345-4363, option 2 and then option 4 to clarify whether you want a copy of the previous results or if you have questions about continuing with testing. The specimen can be retained for 28 days from collection.
chroms previously done '25 18415216080

Immunoglobulin G, Qn, Serum

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Immunoglobulin G, Qn, Serum [02]	926		mg/dL	586-1602

Immunoglobulin A, Qn, Serum

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
▲ **Immunoglobulin A, Qn, Serum [02]**	**354 High**		mg/dL	87-352

Immunoglobulin M, Qn, Serum

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Immunoglobulin M, Qn, Serum [02]	82		mg/dL	26-217

Thyroid Peroxidase (TPO) Ab

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Thyroid Peroxidase (TPO) Ab [02]	<9	<9	07/03/2025	IU/mL	0-34

Disclaimer
The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

Icon Legend
▲ Out of Reference Range ■ Critical or Alert

Comments
A: Results for this test are for research purposes only by the assay's manufacturer. The performance characteristics of this product have not been established. Results should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.

Performing Labs
01: BN - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361 Dir: Sanjai Nagendra, MD
02: MB - Labcorp Birmingham, 1801 First Avenue South, Birmingham, AL 35233-1935 Dir: Steven Wang, MD
03: 2Q - Labcorp Burlington DNA, 1440 York Court, Burlington, NC 27215-3361 Dir: Gloria Haskell, PhD
04: ES - Esoterix Inc, 4301 Lost Hills Road, Calabasas Hills, CA 91301-5358 Dir: Basel Kashlan, MD
05: TG - Labcorp RTP, 1912 TW Alexander Drive, RTP, NC 27709-0150 Dir: Anjen Chenn, MDPhD
For inquiries, the physician may contact Branch: 800-631-5250 Lab: 205-581-3500

Patient Details
Jennis, Ariel
7319 SANCTUARY COVE DR SE, OWENS CROSS ROAD, AL, 35763

Phone: **941-447-4368**
Date of Birth: **04/16/1992**
Age: **33**
Sex: **Female**
Patient ID: **1007021**
Alternate Patient ID: **7983**

Physician Details
R BURNEY
PREGIMMUNE CORP DBA PREGMUNE
344 GROVE ST PMB 60570, JERSEY CITY, NJ, 073025923

Phone: **201-409-4100**
Account Number: **29088990**
Physician ID: **1003958083**
NPI: **1003958083**

Specimen Details
Specimen ID: **224-152-6906-0**
Control ID: **7176**
Alternate Control Number: **7176**
Date Collected: **08/12/2025 1704 Local**
Date Received: **08/12/2025 0000 ET**
Date Entered: **08/12/2025 1848 ET**
Date Reported: **09/02/2025 1805 ET**